Display options
Cite
Er LM, Li Y, Wu ML, et al. Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms. Oncol Lett. 2017;13(4):2391-2396doi: 10.3892/ol.2017.5735.
Er, L. M., Li, Y., Wu, M. L., Zhao, Q., Tan, B. B., Wang, X. L., & Wang, S. J. (2017). Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms. Oncology letters, 13(4), 2391-2396. https://doi.org/10.3892/ol.2017.5735
Er, Li-Mian, et al. "Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms." Oncology letters vol. 13,4 (2017): 2391-2396. doi: https://doi.org/10.3892/ol.2017.5735
Er LM, Li Y, Wu ML, Zhao Q, Tan BB, Wang XL, Wang SJ. Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms. Oncol Lett. 2017 Apr;13(4):2391-2396. doi: 10.3892/ol.2017.5735. Epub 2017 Feb 14. PMID: 28454409; PMCID: PMC5403395.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Apr;13(4):2391-2396. doi: 10.3892/ol.2017.5735. Epub 2017 Feb 14.

Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms.

Oncology letters

Li-Mian Er, Yong Li, Ming-Li Wu, Qun Zhao, Bi-Bo Tan, Xiao-Ling Wang, Shi-Jie Wang

Affiliations

  1. Department of Endoscopy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
  2. The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
  3. Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.

PMID: 28454409 PMCID: PMC5403395 DOI: 10.3892/ol.2017.5735

Abstract

The aim of the present study was to investigate the expression and clinical significance of oncofetal protein insulin-like growth factor (IGF) II mRNA-binding protein 3 (IMP3) in the differentiation of gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN). A total of 162 patients who were diagnosed with GEP-NEN, and who underwent surgical or endoscopic resection from January 2006 to March 2013, were enrolled in the study, including 85 cases of grade (G)1 neuroendocrine tumors, 40 cases of G2 neuroendocrine tumors, 28 cases of G3 neuroendocrine carcinomas and 9 cases of mixed stage adenoneuroendocrine carcinomas. The clinical and pathological data were recorded for analysis. The expression of IMP3, cluster of differentiation (CD)44, IGF1 receptor (IGF1R) and matrix metalloproteinase (MMP)2 was determined by immunohistochemistry. SPSS 13.0 software was used for data processing and analyses, and P<0.05 was used to determine significance. Oncofetal protein IMP3 exhibited a high expression rate (74.69%) in GEP-NEN. IMP3-positive cases demonstrated significantly decreased overall and disease-free survival times, as compared with IMP3-negative cases (P=0.012). Overexpression of IMP3 was correlated with tumor grade, clinical stage, tumor size and poor prognosis (all P<0.05). Therefore, patients with overexpressed IMP3 had a poorer prognosis (P<0.01); COX regression analysis revealed that the overexpression of IMP3, the tumor grade, tumor size and metastasis of GEP-NEN were each associated with the clinical outcomes. The results also indicated that the expression rates of CD44, IGF1R and MMP2 in GEP-NEN were 19.75, 53.7 and 55.56%, respectively. While it was negatively associated with the expression of CD44 (r=-0.131; P=0.096), the expression of IMP3 was positively correlated with the expression of IGF1R and MMP2 (r=0.288, P<0.01; r=0.208, P=0.008). In addition, the expression levels of IGF1R and MMP2 were positively associated (r=0.687; P<0.01). In conclusion, high IMP3 expression levels were determined to be associated with a high disease stage in patients with GEP-NEN, thus it may serve as a predictor for metastasis and poor clinical outcomes in GEP-NEN.

Keywords: gastroenteropancreatic neuroendocrine neoplasms; immunohistochemistry; insulin-like growth factor II mRNA binding protein 3; predictor; prognosis

References

  1. J Clin Oncol. 2008 Jun 20;26(18):3063-72 - PubMed
  2. Expert Opin Ther Targets. 2013 Mar;17(3):307-20 - PubMed
  3. Mod Pathol. 2012 Sep;25(9):1227-35 - PubMed
  4. Mol Cell Biol. 1999 Feb;19(2):1262-70 - PubMed
  5. Biotech Histochem. 2012 Jan;87(1):24-9 - PubMed
  6. Pancreas. 2008 Aug;37(2):134-8 - PubMed
  7. Scand J Clin Lab Invest Suppl. 2001;234:93-9 - PubMed
  8. J Biol Chem. 2011 Jul 22;286(29):25882-90 - PubMed
  9. J Surg Oncol. 2012 Jun 15;105(8):780-5 - PubMed
  10. Gene. 2002 Apr 3;287(1-2):49-54 - PubMed
  11. Virchows Arch. 2010 Jun;456(6):595-7 - PubMed
  12. World J Gastroenterol. 2008 Sep 21;14(35):5377-84 - PubMed
  13. Front Endocrinol (Lausanne). 2014 May 19;5:76 - PubMed
  14. Mech Dev. 1999 Oct;88(1):95-9 - PubMed
  15. Chin Med J (Engl). 2010 Dec;123(24):3554-8 - PubMed
  16. Am J Surg Pathol. 2011 Nov;35(11):1638-45 - PubMed
  17. Ann Surg Oncol. 2009 Dec;16(12):3499-506 - PubMed
  18. J Biol Chem. 2011 Sep 9;286(36):31145-52 - PubMed
  19. Endocr Relat Cancer. 2010 Oct 05;17(4):909-18 - PubMed
  20. J Craniofac Surg. 2011 Nov;22(6):2022-5 - PubMed
  21. Diagn Pathol. 2012 Nov 28;7:165 - PubMed
  22. Hum Pathol. 2011 Mar;42(3):303-14 - PubMed
  23. J Thorac Oncol. 2014 Nov;9(11):1656-61 - PubMed
  24. Semin Cancer Biol. 2014 Dec;29:3-12 - PubMed
  25. Curr Pharm Des. 2014;20(17):2899-911 - PubMed
  26. BMC Cancer. 2015 Apr 11;15:266 - PubMed
  27. Endocr Relat Cancer. 2008 Dec;15(4):1083-97 - PubMed
  28. Med Oncol. 2014 Jan;31(1):805 - PubMed
  29. Cell Mol Life Sci. 2013 Aug;70(15):2657-75 - PubMed

Publication Types